Boston Scientific stock: TD Cowen keeps USD 56 target for Boston Scientific stock

Published on 10/23/2026 at 15:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 5.44 billion, up 7.50 percent year over year. Boston Scientific stock costs EUR 40.80 on October 23, 2026 at 3:33 p.m. CEST.

Analyst target and reporting date

TD Cowen maintained a USD 56.00 target and Buy rating on October 20, 2026.
Second-quarter 2026 revenue reached USD 5.44 billion, up 7.50 percent year over year.
Boston Scientific stock costs EUR 40.80 at Lang & Schwarz on October 23, 2026 at 3:33 p.m. CEST.
Boston Scientific is scheduled to report third-quarter results on October 28, 2026.

Schwarz-Weiß-Reportage: Büroangestellte treten durch Drehtüren eines Bürogebäudes — Boston Properties US1011371077 dokumentiert Angestellte beim Betreten eines klassischen amerikanischen Büroturms in der Innenstadt, Illustration mit AI erstellt.

Boston Scientific received a maintained USD 56.00 price target and Buy rating from TD Cowen on October 20, 2026, while second-quarter revenue reached USD 5.44 billion. Investing.com reported that the firm kept its target despite near-term pressure linked to a cyberattack. Boston Scientific was trading at EUR 40.80 at Lang & Schwarz on October 23, 2026 at 3:33 p.m. CEST.

Revenue growth remains measurable

Revenue for the second quarter of 2026 was USD 5.44 billion, compared with USD 5.06 billion in the second quarter of 2025. That equals 7.50 percent year-over-year growth. Net profit reached USD 907 million for the quarter, versus USD 793 million a year earlier, according to Markets Insider.

Stock remains near its yearly low

On the NYSE, Boston Scientific was trading at USD 45.95 at 9:41 a.m. ET on October 23, 2026. Its 52-week range was USD 41.39 to USD 105.65, placing the quoted price USD 4.56 above the low and USD 59.70 below the high. The market capitalization was USD 66.6 billion, and the price-to-earnings ratio was 18.65.

Target and reporting date matter

TD Cowen's USD 56.00 target stands USD 10.05 above the NYSE price of USD 45.95, a 21.87 percent premium to that price. The firm linked its view to the 2027 outlook while describing the cyberattack as a near-term issue. Boston Scientific is scheduled to report third-quarter results on October 28, 2026, according to Investing.com.

Comparison with peers

Boston Scientific: price-to-earnings ratio 18.65, market capitalization USD 66.6 billion.

Medtronic (NYSE, USD): price-to-earnings ratio 23.80, dividend yield 3.00 percent, market capitalization USD 123.8 billion.

Abbott Laboratories (NYSE, USD): price-to-earnings ratio 38.26, dividend yield 2.00 percent, market capitalization USD 179.1 billion.

What comes next for investors

The October 28 results will put the third-quarter outlook alongside the latest revenue trend. The contrast is clear: second-quarter revenue grew 7.50 percent, while TD Cowen's target reflects a higher valuation than the current NYSE quote.

Boston Scientific was trading at EUR 40.80 at Lang & Schwarz on October 23, 2026 at 3:33 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Boston Scientific stock.